PSA Progression: Clinical Trials

7 trials for PSA Progression, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 27Completed 7

Follow PSA Progression: new trials by email Literature Review of PSA Progression trials Research Report on PSA Progression

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
Gallium Ga 68 DOTA-NeoBOMB1, Gallium Ga 68 PSMA-R2 - Prostate Adenocarcinoma, PSA Progression
Phase 2CompletedAndrei Iagaru272020-12-152024-01-30
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer
Apalutamide, Stereotactic Body Radiation Therapy - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Phase 2CompletedUniversity of California, San Francisco262019-12-172026-01-21
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Phase 2CompletedBarbara Ann Karmanos Cancer Institute152018-06-072023-05-03
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
Computed Tomography, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Phase 2CompletedJonsson Comprehensive Cancer Center9372018-04-022021-09-30
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
ESK981 - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Phase 2CompletedBarbara Ann Karmanos Cancer Institute132018-03-082023-07-14
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
Carboplatin, Docetaxel, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Phase 2CompletedUniversity of Washington142016-01-262022-11-17
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
Enzalutamide, Laboratory Biomarker Analysis, Pembrolizumab - Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer
Phase 2CompletedOHSU Knight Cancer Institute582014-11-182026-10-28

Narrower conditions

Prostatic Neoplasms (5)

Broader conditions

Genital Diseases (5)  ·  Genital Diseases, Male (5)  ·  Genital Neoplasms, Male (5)  ·  Male Urogenital Diseases (5)  ·  Neoplasms (5)  ·  Neoplasms by Site (5)  ·  Prostatic Diseases (5)  ·  Urogenital Diseases (5)  ·  Urogenital Neoplasms (5)

Interventions

pembrolizumab (2)  ·  68Ga-DKFZ-PSMA-11 (1)  ·  Carboplatin (1)  ·  Docetaxel (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Radiosurgery (1)  ·  apalutamide (1)  ·  enzalutamide (1)  ·  gallium 68 PSMA-11 (1)

Sponsors

Barbara Ann Karmanos Cancer Institute (2)  ·  Andrei Iagaru (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  OHSU Knight Cancer Institute (1)  ·  University of California, San Francisco (1)  ·  University of Washington (1)

Countries

United States (7)

Top investigators

Abhinav Deol, M.D. (1)  ·  Andrei Iagaru (1)  ·  Elisabeth I. Heath (1)  ·  Heather H. Cheng (1)  ·  Jeremie Calais (1)  ·  Julie Graff, M.D. (1)  ·  Rahul Aggarwal, MD (1)

Results publications

PMID 32616555, PMID 33602654, PMID 37981040, PMID 38664016, PMID 39227508, PMID 41698328

NIH funding

P30CA022453 (2), P30CA015704 (1), P50CA097186 (1)